New Analyses Confirm Patients with Medtronic CRT Devices Experience Less Atrial Fibrillation, Are More Active

Two real-world analyses featuring the Medtronic (NYSE: MDT) AdaptivCRT algorithm reinforce that its use is linked to a reduction in atrial fibrillation (AF) episodes, as well as tied to higher patient activity levels. The results, involving 408 patients with heart failure and a Medtronic cardiac resynchronization therapy (CRT) device at 26 centers in Italy, were unveiled at the European Heart Rhythm Association (EHRA) Scientific Sessions 2018 in Barcelona, Spain.

As quoted in the press release:

“Atrial fibrillation is a common comorbidity among patients with heart failure,” said Professor Alessandro Proclemer M.D., of University Hospital Santa Maria della Misericordia, Udine, Italy. “Progression of AF is linked to an increased risk of stroke and death, so it is encouraging to see additional clinical data that again links AdaptivCRT with a reduction in the incidence of AF in these patients.”

Click here to read the full press release.